AMAL Therapeutics to publish latest findings of its in vivo research team, in collaboration with Medical University of Innsbruck, on Nature Communication website

Geneva, Switzerland, August 31, 2021 - AMAL Therapeutics announced today that the latest findings of its in vivo research team, in collaboration with Prof. Guido Wollman’s lab at the Medical University of Innsbruck, is online on the Nature Communication website. The results show that combinatorial treatment with a protein-based cancer vaccine and an oncolytic virus elicits a potent immune response resulting in long lasting anti-tumoral efficacy in different tumor models, highlighting the potential for cancer treatment.

PDF icon View full article in .pdf

Share this entry

You are now leaving our website

Using this link will let you leave a website of Amal Therapeutics or to a different domain under the control of Amal Therapeutics. In the event that the linked site is not under the control of Amal Therapeutics but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, Amal Therapeutics shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites.

This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Amal Therapeutics of the site.

Target URL: